ENLIVEN THERAPEUTICS
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives. The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectively develop precision oncology therapeutics that enhance overall patient well-being. Founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD, Enliven Therapeutics is based in Boulder, Colorado.
ENLIVEN THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Therapeutics
Founded:
2019-01-01
Address:
Boulder, Colorado, United States
Country:
United States
Website Url:
http://www.enliventherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
140 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Apache Global Site Tag
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Alloy Therapeutics
Alloy Therapeutics is a biotech company that makes medicine by democratizing access to foundational drug discovery platforms and services.
Altay Therapeutics
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for chronic inflammatory conditions.
Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Calithera Biosciences
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Galera Therapeutics
Galera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Gallant Pet
Gallant Pet is a pet service company that develops a stem cell therapy intended for dog wounds.
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Kanaph Therapeutics
Kanaph Therapeutics is a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules.
MDI Therapeutics
MDI Therapeutics is a operator of an discovery stage company focused on developing novel therapies for fibrotic diseases.
Mitobridge
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions.
NeuroNascent
Neuronascent discovers and develops small molecule therapeutics for depression and neurodegenerative diseases.
Phoenicis
Phoenicis focuses on developing therapies to provide hope and relief to people living with rare disease.
Restore Vision
Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa.
Scorpion Therapeutics
Scorpion Therapeutics is a precision oncology company that broadens the reach and impact of precision medicine for cancer patients.
Signum Biosciences
Signum Biosciences develops small molecule therapeutics derived from its STM platform to modulate signal transduction imbalances.
SiteOne Therapeutics
SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics.
Strand Therapeutics
Strand Therapeutics is a biopharmaceutical company applying synthetic biology to RNA therapeutics to develop single dose mRNA treatments.
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.
SyntheX
SyntheX is a biotechnology company reimagining precision therapeutics with new drug discovery technologies focused on protein modulation.
Current Advisors List
Current Employees Featured
Founder
Investors List
Surveyor Capital
Surveyor Capital investment in Series B - Enliven Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Enliven Therapeutics
Boxer Capital
Boxer Capital investment in Series B - Enliven Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Enliven Therapeutics
Logos Capital
Logos Capital investment in Series B - Enliven Therapeutics
OrbiMed
OrbiMed investment in Series A - Enliven Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series A - Enliven Therapeutics
5AM Ventures
5AM Ventures investment in Series A - Enliven Therapeutics
OrbiMed
OrbiMed investment in Seed Round - Enliven Therapeutics
5AM Ventures
5AM Ventures investment in Seed Round - Enliven Therapeutics
Official Site Inspections
http://www.enliventherapeutics.com Semrush global rank: 9.7 M Semrush visits lastest month: 114
- Host name: ec2-54-176-110-96.us-west-1.compute.amazonaws.com
- IP address: 54.176.110.96
- Location: San Jose United States
- Latitude: 37.3388
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95141
More informations about "Enliven Therapeutics"
Enliven Therapeutics | Small Molecule Kinase Inhibitors
Novel Insights, Precision Therapeutics. We are developing kinase inhibitors that enhance efficacy through better selectivity and combinability, combat …See details»
Enliven Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives. The company's discovery process combines clinically validated …See details»
Careers and Job Opportunities | Enliven Therapeutics
Passion. We love what we do. Fueled by spirited curiosity, we always strive to excel and remain mindful of the importance of our team roles. Plus, we pay it forward, always seeking …See details»
Enliven Therapeutics - LinkedIn
Enliven Therapeutics | 4,291 followers on LinkedIn. Discovering and developing next generation precision oncology therapeutics | Enliven Therapeutics is a biopharmaceutical company focused on the ...See details»
Enliven Therapeutics, Inc. (ELVN) Company Profile & Overview
Ticker Symbol: ELVN: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $16.00: CIK Code: 0001672619: CUSIP Number: 29337E102 ...See details»
Enliven Therapeutics - Overview, News & Similar companies
Apr 16, 2024 Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the …See details»
ENLIVEN THERAPEUTICS PROVIDES CORPORATE UPDATE ON …
Jan 19, 2022 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven" or the "Company"), a precision oncology company focused on the discovery and development of...See details»
Enliven Therapeutics - Company Profile & Staff Directory
Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven …See details»
Release Details - Enliven Therapeutics
Feb 23, 2023 Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under the new ticker symbol …See details»
Enliven Therapeutics Inc, ELVN:NSQ profile - FT.com - Financial …
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer.See details»
Enliven Therapeutics Announces $90 Million Private Placement …
Mar 19, 2024 Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend …See details»
Precision Oncology Therapeutics | Enliven Therapeutics
The Enliven Difference. We strive to improve survival and overall well-being for cancer patients. Despite the advancement of precision medicine in oncology, a significant unmet need remains …See details»
Enliven Therapeutics to Present at the Jefferies London Healthcare ...
BOULDER, Colo., Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the …See details»
Enliven Therapeutics Launches With Vision Of Advancing Medicine …
BOULDER, Colo., Dec. 7, 2020 /PRNewswire/ -- Enliven Therapeutics, a precision oncology company based in Boulder, CO, is announcing its launch from stealth with a bold mission: To …See details»
Enliven Therapeutics and Imara Announce Merger Agreement
Oct 13, 2022 Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is …See details»
Enliven Therapeutics Reports Third Quarter Financial Results and ...
Sep 30, 2024 Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 …See details»
Pipeline | BCR-ABL | ELVN-001 | HER2 | Enliven Therapeutics
BCR-ABL Program: ELVN-001. ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for …See details»
Enliven Therapeutics Announces Positive Proof of Concept Data …
Apr 11, 2024 The event will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com. To participate …See details»
Enliven Therapeutics Announces Positive Proof of Concept Data …
Apr 11, 2024 Patient Demographics. As of the cutoff date, March 18, 2024, 27 patients had enrolled in the ongoing Phase 1 clinical trial across five dose levels of ELVN-001, ranging from …See details»